MIRM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

135.72M

+36.52%

-0.063

-87.08%

141.61M

+26.91%

-0.048

-83.89%

147.88M

+15.73%

-0.070

-41.67%

Estimates Revision

The market is revising No Change the revenue expectations for Mirum Pharmaceuticals, Inc. (MIRM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 10.54%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-44.73%

In Past 3 Month

Stock Price

Go Up

+10.54%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

77.00

Averages

88.11

High

95.00

Current: 0.000

Low

77.00

Averages

88.11

High

95.00

Citizens

Jonathan Wolleben

Outperform

maintain

$95 -> $140

2025-12-19

Reason

Citizens

Jonathan Wolleben

Price Target

$95 -> $140

2025-12-19

maintain

Outperform

Reason

Citizens analyst Jonathan Wolleben raised the firm's price target on Mirum Pharmaceuticals to $140 from $95 and keeps an Outperform rating on the shares. Mirum has outperformed year to date and is expected to continue leading in 2026, supported by multiple high-confidence pivotal readouts across its pipeline, the analyst tells investors in a research note. The brelovitug acquisition adds a late-stage asset with near-term data, while volixibat's pivotal readout in 2Q26 for primary sclerosing cholangitis drives increased confidence and a higher probability of success, the firm says.

Leerink

Outperform

maintain

$90 -> $100

2025-12-10

Reason

Leerink

Price Target

$90 -> $100

2025-12-10

maintain

Outperform

Reason

Leerink raised the firm's price target on Mirum Pharmaceuticals to $100 from $90 and keeps an Outperform rating on the shares. The firm updated its Mirum model for the Bluejay acquisition terms and concurrent Private Investment in Public Equity, both expected to close in Q1. Meanwhile, clinical development and commercialization of brelovitug is expected to require about $250M over the next two years, and Mirum will pay up to $200M in tiered sales milestones, the analyst tells investors in a research note. Following encouraging Phase 2 ddata for brelovitug for the treatment of chronic hepatitis delta, Phase 3 interim data is expected in 2Q26 and topline results in 2H26, the analyst adds.

Baird

Outperform

maintain

$80 -> $88

2025-12-09

Reason

Baird

Price Target

$80 -> $88

2025-12-09

maintain

Outperform

Reason

Baird raised the firm's price target on Mirum Pharmaceuticals to $88 from $80 and keeps an Outperform rating on the shares. The firm updated its model following its Blujay acquisition which brings in an attractive opportunity in HDV.

Morgan Stanley

Michael Ulz

Overweight

maintain

$81 -> $95

2025-12-09

Reason

Morgan Stanley

Michael Ulz

Price Target

$81 -> $95

2025-12-09

maintain

Overweight

Reason

Morgan Stanley analyst Michael Ulz raised the firm's price target on Mirum Pharmaceuticals to $95 from $81 and keeps an Overweight rating on the shares. The acquisition of Bluejay adds brelovitug, which has demonstrated "promising activity and tolerability" in hepatitis delta virus and expands rare liver disease pipeline while providing synergies, the analyst tells investors.

Cantor Fitzgerald

Overweight

maintain

$95 -> $130

2025-12-08

Reason

Cantor Fitzgerald

Price Target

$95 -> $130

2025-12-08

maintain

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Mirum Pharmaceuticals to $130 from $95 and keeps an Overweight rating on the shares. Mirum's proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $200M in tiered milestone payments is a "steal," the analyst tells investors in a research note.

Cantor Fitzgerald

Overweight

maintain

$85 -> $95

2025-11-05

Reason

Cantor Fitzgerald

Price Target

$85 -> $95

2025-11-05

maintain

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Mirum Pharmaceuticals to $95 from $85 and keeps an Overweight rating on the shares. This was a profitable quarter for Mirum as it gradually transitions to an earnings growth story, and Cantor expects considerable inflection in EPS in 2027 and beyond, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM.O) is -306.16, compared to its 5-year average forward P/E of -18.57. For a more detailed relative valuation and DCF analysis to assess Mirum Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.57

Current PE

-306.16

Overvalued PE

143.71

Undervalued PE

-180.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.36

Current EV/EBITDA

63.42

Overvalued EV/EBITDA

59.98

Undervalued EV/EBITDA

-86.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.52

Current PS

6.96

Overvalued PS

9.34

Undervalued PS

3.71

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 301.43% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 301.43% over the last month.

Sold

Bought

MIRM News & Events

Events Timeline

No data

News

5.0

01-04NASDAQ.COM

Small-Cap and Renewable Energy Stocks Expected to Perform Well in 2026

5.0

01-04Fool

2026 Stock Market Predictions: Small-Cap Stocks to Rise

2.0

2025-12-30NASDAQ.COM

Fox's Market Cap of $31 Billion Expected to Exceed Newsmax

People Also Watch

Frequently Asked Questions

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

The current price of MIRM is 81.6 USD — it has decreased -0.46 % in the last trading day.

What is Mirum Pharmaceuticals Inc (MIRM)'s business?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

What is the price predicton of MIRM Stock?

What is Mirum Pharmaceuticals Inc (MIRM)'s revenue for the last quarter?

Mirum Pharmaceuticals Inc revenue for the last quarter amounts to 133.01M USD, increased 47.17 % YoY.

What is Mirum Pharmaceuticals Inc (MIRM)'s earnings per share (EPS) for the last quarter?

Mirum Pharmaceuticals Inc. EPS for the last quarter amounts to 0.05 USD, decreased -116.67 % YoY.

What changes have occurred in the market's expectations for Mirum Pharmaceuticals Inc (MIRM)'s fundamentals?

How many employees does Mirum Pharmaceuticals Inc (MIRM). have?

Mirum Pharmaceuticals Inc (MIRM) has 322 emplpoyees as of January 09 2026.

What is Mirum Pharmaceuticals Inc (MIRM) market cap?

Today MIRM has the market capitalization of 4.22B USD.